Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Post Earnings of -$0.09 Per Share

Share on StockTwits

Equities research analysts forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will post ($0.09) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings. The highest EPS estimate is $0.00 and the lowest is ($0.16). Lexicon Pharmaceuticals reported earnings of ($0.33) per share in the same quarter last year, which would indicate a positive year over year growth rate of 72.7%. The business is expected to report its next quarterly earnings results on Monday, July 29th.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($0.47) per share for the current year, with EPS estimates ranging from ($0.78) to $0.31. For the next year, analysts expect that the company will post earnings of ($0.62) per share, with EPS estimates ranging from ($1.23) to ($0.05). Zacks’ EPS averages are an average based on a survey of research firms that cover Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $13.26 million. During the same quarter last year, the business posted ($0.40) EPS. The company’s quarterly revenue was down 63.8% compared to the same quarter last year.

Several brokerages have recently issued reports on LXRX. BidaskClub lowered Westport Fuel Systems from a “buy” rating to a “hold” rating in a research report on Friday. Wedbush set a $175.00 target price on Lululemon Athletica and gave the stock a “hold” rating in a research report on Tuesday, June 11th. Gabelli raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, March 25th. Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. Finally, Stifel Nicolaus set a $99.00 target price on C.H. Robinson Worldwide and gave the stock a “hold” rating in a research report on Monday, March 25th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $16.38.

Several large investors have recently made changes to their positions in the company. Gamco Investors INC. ET AL raised its position in shares of Lexicon Pharmaceuticals by 10.0% in the 1st quarter. Gamco Investors INC. ET AL now owns 22,000 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 2,000 shares in the last quarter. CWM Advisors LLC increased its position in Lexicon Pharmaceuticals by 30.2% during the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 3,030 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Lexicon Pharmaceuticals by 940.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 8,979 shares in the last quarter. Pinnacle Associates Ltd. increased its position in Lexicon Pharmaceuticals by 1.8% during the 1st quarter. Pinnacle Associates Ltd. now owns 550,549 shares of the biopharmaceutical company’s stock valued at $3,061,000 after buying an additional 9,615 shares in the last quarter. Finally, Wealth & Pension Services Group Inc. bought a new position in Lexicon Pharmaceuticals during the 1st quarter valued at approximately $60,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:LXRX traded down $0.05 during trading on Friday, hitting $5.28. The stock had a trading volume of 565,251 shares, compared to its average volume of 325,812. Lexicon Pharmaceuticals has a 12 month low of $4.25 and a 12 month high of $13.13. The company has a market cap of $566.43 million, a P/E ratio of -4.63 and a beta of 0.84. The company has a fifty day moving average of $5.89.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.